Opus Genetics, Inc.是一家臨床階段的眼科生物製藥公司,致力於開發和商業化用於治療多種眼疾的療法。Ocuphire的產品線目前包括針對眼部適應症的兩種小分子候選產品。該公司的主要產品候選產品Nyxol眼藥水是一種每日一次無防腐劑的甲磺酸酚妥拉明的眼藥水配方,一種非選擇性的α-1和α-2腎上腺素能拮抗劑,旨在減少瞳孔大小,目前正在開發有幾種適應症,包括昏暗的燈光或夜視障礙,藥理性散瞳和老花眼。Ocuphire的第二個候選產品APX3330是每天兩次的口服片劑,旨在抑制與視網膜和脈絡膜血管疾病(例如糖尿病性視網膜病變和糖尿病性黃斑水腫)相關的血管生成和炎症途徑。
董事
名稱
職位
Cam Gallagher
Independent Chairman of the Board and Director
George Magrath
Chief Executive Officer, Director
James S. Manuso
Independent Director
Sean Ainsworth
Independent Director
Susan K. Benton
Independent Director
Adrienne Graves
Director
Benjamin R. Yerxa
Director
Jean Bennett
Director
Richard J. Rodgers
董事
股東
名稱
職位
George Magrath
Chief Executive Officer, Director
Joseph Schachle
Chief Operating Officer
Amy Rabourn
Senior Vice President of Finance
Bernhard Hoffmann
Senior Vice President of Corporate Development
Robert Gagnon
Chief Financial Officer and Principal Accounting Officer